The benefit and risk of nivolumab in non‐small‐cell lung cancer: a single‐arm meta‐analysis of noncomparative clinical studies and randomized controlled trials

Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. Although it is used for treating advanced non‐small‐cell lung cancer (NSCLC), its actual efficacy has not been determined. We searched PubMed, the Cochrane Library, Embase, MEDLI...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Binghao, Zhang, Wenxiong, Yu, Dongliang, Xu, Jianjun, Wei, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943422/
https://www.ncbi.nlm.nih.gov/pubmed/29573217
http://dx.doi.org/10.1002/cam4.1387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943422/
https://www.ncbi.nlm.nih.gov/pubmed/29573217
http://dx.doi.org/10.1002/cam4.1387

Ejemplares similares